Sanofi CEO Paul Hudson continues hunt for new tech, spearing a deal with organoid startup
Sanofi is dipping its toes into a wide range of new technologies as CEO Paul Hudson looks to find its next big breakthrough. His latest pick comes from an emerging field that’s had plenty of buzz but few tangible results in drug development so far.
The French pharma announced on Tuesday a deal with Prellis Biologics, a new biotech that claims to have developed an organoid system in its labs that can mimic the human immune system. Although the startup has only raised a modest sum by modern biotech standards — it announced a $14.5 million Series B in December — its technology has attracted the interest of large companies. In January, the company also announced a licensing deal with Bristol Myers Squibb.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.